Lanean...

Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections

Twenty patients with carbapenem-resistant Enterobacteriaceae infections were treated with meropenem-vaborbactam. Thirty-day clinical success and survival rates were 65% (13/20) and 90% (18/20), respectively. Thirty-five percent of patients had microbiologic failures within 90 days. One patient devel...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Infect Dis
Egile Nagusiak: Shields, Ryan K, McCreary, Erin K, Marini, Rachel V, Kline, Ellen G, Jones, Chelsea E, Hao, Binghua, Chen, Liang, Kreiswirth, Barry N, Doi, Yohei, Clancy, Cornelius J, Nguyen, M Hong
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2020
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7768741/
https://ncbi.nlm.nih.gov/pubmed/31738396
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/ciz1131
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!